Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Non Operating Income: 2010-2024

Historic Non Operating Income for Heron Therapeutics (HRTX) over the last 14 years, with Dec 2024 value amounting to -$2.1 million.

  • Heron Therapeutics' Non Operating Income fell 428.97% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.8 million, marking a year-over-year decrease of 136.64%. This contributed to the annual value of -$2.1 million for FY2024, which is 466.43% down from last year.
  • As of FY2024, Heron Therapeutics' Non Operating Income stood at -$2.1 million, which was down 466.43% from $560,000 recorded in FY2023.
  • Heron Therapeutics' Non Operating Income's 5-year high stood at $885,000 during FY2020, with a 5-year trough of -$7.4 million in FY2022.
  • Its 3-year average for Non Operating Income is -$3.0 million, with a median of -$2.1 million in 2024.
  • Its Non Operating Income has fluctuated over the past 5 years, first spiked by 107.60% in 2023, then tumbled by 466.43% in 2024.
  • Yearly analysis of 5 years shows Heron Therapeutics' Non Operating Income stood at $885,000 in 2020, then plummeted by 422.60% to -$2.9 million in 2021, then plummeted by 158.00% to -$7.4 million in 2022, then skyrocketed by 107.60% to $560,000 in 2023, then plummeted by 466.43% to -$2.1 million in 2024.